Literature DB >> 18758643

Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival.

Daniela Lazăr1, Sorina Tăban, Carmen Ardeleanu, Cristiana Simionescu, I Sporea, Marioara Cornianu, Corina Vernic.   

Abstract

INTRODUCTION: The mechanisms by which COX-2 contributes to the carcinogenesis are not known until present. It seems that the COX-2 enzyme stimulates the cell proliferation, inhibits the apoptosis, increases the malignant cells' invasiveness and induces the angiogenesis by elaborating some angiogenic factors.
MATERIAL AND METHODS: In the present study, we intend to evaluate the immunohistochemical expression of COX-2 in gastric carcinomas, keeping track of the correlations between the clinicopathologic factors, the tumor angiogenesis (evaluated by microvascular density--MVD--determination and by VEGF expression) and the patients' survival. In addition, we have tracked the immunoreactions' positivation in the peritumoral mucosa with various lesions, with the purpose to establish the contribution of COX-2 to the gastric carcinogenesis during the pre-invasive stages. A prospective study was realized, regarding the evolution and aggressiveness of the gastric cancer, with a duration of five years, 61 patients operated of gastric cancer being included.
RESULTS: The COX-2 immunoreactions have been significantly more frequent noticed in the gastric carcinomas included in the study (57.4%) and in the epithelial dysplasia areas adjacent to the carcinomas of intestinal type (35.5% of the cases), than in the normal peritumoral mucosa (4.9%) (p<0.001 ES). The COX-2 immunoreactions have turned positive more frequently in gastric carcinomas of intestinal type (68.4%), in comparison to the carcinomas of diffuse type (29.4%) (p<0.001 ES). The COX-2 expression is significantly correlated with the invasion level, the presence of the metastases in the regional lymph nodes and the pTNM stage, but without influencing the prognosis of the gastric cancer patients. The negative VEGF carcinomas have turned positive for COX-2 only for 19% of the cases. Different from those, the positive VEGF carcinomas have associated COX-2 immunoreactivity in 77.5% of the cases.
CONCLUSIONS: The results obtained are suggestive for the predominant expression of COX-2 in the carcinomas of intestinal type and its precursory lesions. Our results show a tight correlation between the immunohistochemical expressions of COX-2 and VEGF in gastric carcinomas (r = 0.562, p < 0.001 ES) and also a MVD average value significantly higher in the positive COX-2 carcinomas, suggesting an intense angiogenesis activity in that group of tumors (p < 0.001 ES).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758643

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  7 in total

Review 1.  Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis.

Authors:  Jian Song; Hong Su; Yang-Yang Zhou; Liang-Liang Guo
Journal:  Dig Dis Sci       Date:  2013-11-01       Impact factor: 3.199

2.  Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer.

Authors:  M S Al-Moundhri; I Al-Hadabi; K Al-Mawaly; S Kumar; F A R Al-Lawati; G Bhatnager; S Kuruvila; A Al-Hamdani; S M El-Sayed; B Al-Bahrani
Journal:  Med Oncol       Date:  2011-11-03       Impact factor: 3.064

3.  Methylation status and overexpression of COX-2 in Tunisian patients with ductal invasive breast carcinoma.

Authors:  Sondes Karray-Chouayekh; Fatma Trifa; Abdelmajid Khabir; Noureddine Boujelbene; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  Tumour Biol       Date:  2010-12-10

4.  Differential Cytotoxicity but Augmented IFN-γ Secretion by NK Cells after Interaction with Monocytes from Humans, and Those from Wild Type and Myeloid-Specific COX-2 Knockout Mice.

Authors:  Han-Ching Tseng; Aida Arasteh; Kawaljit Kaur; Anna Kozlowska; Paytsar Topchyan; Anahid Jewett
Journal:  Front Immunol       Date:  2015-06-09       Impact factor: 7.561

5.  A preliminary evaluation of oxidative stress in patients with gastric cancer before chemotherapy.

Authors:  Jarosław A Jakubik; Joanna Kołodziejczyk-Czepas; Magdalena Kędzierska; Michał Kaczmarek; Paweł Nowak; Piotr Potemski; Arkadiusz Jeziorski
Journal:  Arch Med Sci       Date:  2021-03-18       Impact factor: 3.318

6.  miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models.

Authors:  Xuan Liu; Qing Ji; Chengcheng Zhang; Xiaowei Liu; Yanna Liu; Ningning Liu; Hua Sui; Lihong Zhou; Songpo Wang; Qi Li
Journal:  Sci Rep       Date:  2017-08-02       Impact factor: 4.379

7.  Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling.

Authors:  Sung-Hwa Sohn; Bohyun Kim; Hee Jung Sul; Bo Youn Choi; Hyeong Su Kim; Dae Young Zang
Journal:  Onco Targets Ther       Date:  2020-02-03       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.